This is a summary of the natural history of MASH, which reviews the key characteristics and epidemiology of different disease stages.
UK-PP-DS-00019 | June 2026
This image of a healthcare professional was generated using artificial intelligence.
A dedicated hub providing key information on metabolic dysfunction-associated steatohepatitis (MASH), useful educational resources to support clinical practice, and news about upcoming events.
Image of fibrotic liver from MASH progression leavepiece.
MASH is a rapidly growing public health concern in the UK, with a prevalence of approximately 5%.1
It is often clinically silent allowing undetected disease progression.2,3
Worsening fibrosis increases the risk of complications and mortality, emphasising the need for timely intervention.4-6
Event details and useful resources from key congresses in the MASH community.
Don’t miss any updates by registering your details.
These resources aim to improve understanding of MASH and support clinical practice.
This is a summary of the natural history of MASH, which reviews the key characteristics and epidemiology of different disease stages.
UK-PP-DS-00019 | June 2026
This is a guidelines-based algorithm for the non-invasive risk stratification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD), and a summary of risk-related thresholds for relevant investigations.
UK-PP-DS-00019 | June 2026
Focused on routine diabetes care, this practical resource highlights how to identify patients at risk of MASLD/MASH, outlining key at‑risk populations and the role of FIB‑4 as an accessible first‑line tool to support early fibrosis risk stratification.
UK-PP-DS-00019 | June 2026
An expert overview from BSG 2025, where Dr Lynsey Corless outlines the burden of MASLD and MASH, covering epidemiology, comorbidities, disease progression, and the impact of fibrosis on clinical outcomes.
UK-PP-DS-00019 | June 2026
Using a fictional patient case, Prof Daniel Forton presents a case‑based session from BSG 2025 exploring the diagnosis and risk stratification of MASLD/MASH, with focus on non‑invasive tests and structured approaches to identifying patients at increased risk of liver‑related outcomes.
UK-PP-DS-00019 | June 2026
At DUK 2026, Professor Jeremy Tomlinson and Professor Matthew Armstrong explore key drivers of MASLD/MASH progression, focusing on underlying metabolic mechanisms and their link to type 2 diabetes and multi‑organ disease burden.
UK-PP-DS-00019 | June 2026
An expert‑led session from DUK 2026 in which Professor Jeremy Tomlinson outlines the bidirectional relationship between MASLD/MASH and type 2 diabetes, highlighting fibrosis burden, liver‑related outcomes, and the role of glycaemic control.
UK-PP-DS-00019 | June 2026
Through a case‑based discussion at DUK 2026, Professor Jeremy Tomlinson and Professor Matthew Armstrong examine liver risk assessment in MASLD/MASH, focusing on the use of non‑invasive tests and structured approaches to identifying and stratifying fibrosis risk.
UK-PP-DS-00019 | June 2026
Visit the Madrigal UK website for corporate information, company news and additional resources.
Reference ID
Citation
Ref-01
Ref-02
Ref-03
Younossi ZM et al. Clin Gastroenterol Hepatol. 2026;24(4):1016–34.
Luthra R, Sheth A. Adv Ther. 2025;42:1165–95.
Povsic M et al. Adv Ther. 2019;36(7):1574–94.
Ref-04
Ref-05
Ref-06
Nabi O et al. Dig Dis Sci. 2022;67(6):2584–93.
Taylor RS et al. Gastroenterology. 2020;158:1611–25.e12.
EASL, EASD, EASO. J Hepatol 2024;81:492–542.
To report an adverse event related to a Madrigal product, reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Madrigal on +44 800 031 8910 & [email protected].
This Madrigal portal is for UK healthcare professionals (HCPs) only.